Checkpoint Inhibitor

OCALA, Fla. — September 22, 2026 AIM ImmunoTech Inc. highlighted the potential role of Ampligen® (rintatolimod) in pancreatic cancer...

CHICAGO — September 22, 2026 MAIA Biotechnology announced that enrollment has reached 65 patients in the pivotal Phase 3...

CHICAGO — September 16, 2026 MAIA Biotechnology, Inc. announced that the first U.S. patient has been dosed in the...

Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...

MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...

SAN DIEGO, July 20, 2026 Oncolytics Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

SAN DIEGO – May 8, 2026 Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...

Kenilworth, N.J., October 29, 2025— Merck & Co., Inc. (NYSE: MRK), known as MSD outside the U.S. and Canada,...